Frontiers in Immunology (Apr 2018)
CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells
- Ayako Kurioka,
- Cormac Cosgrove,
- Yannick Simoni,
- Bonnie van Wilgenburg,
- Alessandra Geremia,
- Sophia Björkander,
- Eva Sverremark-Ekström,
- Christine Thurnheer,
- Huldrych F. Günthard,
- Huldrych F. Günthard,
- Nina Khanna,
- The Swiss HIV Cohort Study,
- Oxford IBD Cohort Investigators,
- Lucy Jane Walker,
- Carolina V. Arancibia-Cárcamo,
- Evan W. Newell,
- Christian B. Willberg,
- Christian B. Willberg,
- Paul Klenerman,
- Paul Klenerman,
- V Aubert,
- M Battegay,
- E Bernasconi,
- J Böni,
- DL Braun,
- HC Bucher,
- C Burton-Jeangros,
- A Calmy,
- M Cavassini,
- G Dollenmaier,
- M Egger,
- L Elzi,
- J Fehr,
- J Fellay,
- H Furrer,
- CA Fux,
- M Gorgievski,
- H Günthard,
- D Haerry,
- B Hasse,
- HH Hirsch,
- M Hoffmann,
- I Hösli,
- C Kahlert,
- L Kaiser,
- O Keiser,
- T Klimkait,
- R Kouyos,
- H Kovari,
- B Ledergerber,
- G Martinetti,
- B Martinez de Tejada,
- C Marzolini,
- K Metzner,
- N Müller,
- D Nadal,
- D Nicca,
- G Pantaleo,
- A Rauch,
- S Regenass,
- C Rudin,
- A Scherrer,
- P Schmid,
- R Speck,
- M Stöckle,
- P Tarr,
- A Trkola,
- P Vernazza,
- R Weber,
- S Yerly,
- CV Arancibia-Cárcamo,
- A Bailey,
- E Barnes,
- B Bird-Lieberman,
- O Brain,
- B Braden,
- J Collier,
- J East,
- A Geremia,
- L Howarth,
- S Keshav,
- P Klenerman,
- S Leedham,
- R Palmer,
- F Powrie,
- A Rodrigues,
- A Simmons,
- P Sullivan,
- SPL Travis,
- H Uhlig
Affiliations
- Ayako Kurioka
- The Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, United Kingdom
- Cormac Cosgrove
- Ragon Institute of Massachusetts General Hospital, Harvard University, Massachusetts Institute of Technology, Cambridge, MA, United States
- Yannick Simoni
- Agency for Science, Technology and Research (A*STAR), Singapore Immunology Network (SIgN), Singapore, Singapore
- Bonnie van Wilgenburg
- The Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, United Kingdom
- Alessandra Geremia
- Translational Gastroenterology Unit, Experimental Medicine Division, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
- Sophia Björkander
- Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
- Eva Sverremark-Ekström
- Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
- Christine Thurnheer
- Division of Infectious Diseases, University Hospital Berne, University of Berne, Berne, Switzerland
- Huldrych F. Günthard
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
- Huldrych F. Günthard
- Institute of Medical Virology, University of Zurich, Zurich, Switzerland
- Nina Khanna
- Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland
- The Swiss HIV Cohort Study
- Oxford IBD Cohort Investigators
- Lucy Jane Walker
- 0Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
- Carolina V. Arancibia-Cárcamo
- Translational Gastroenterology Unit, Experimental Medicine Division, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
- Evan W. Newell
- Agency for Science, Technology and Research (A*STAR), Singapore Immunology Network (SIgN), Singapore, Singapore
- Christian B. Willberg
- The Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, United Kingdom
- Christian B. Willberg
- 1NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
- Paul Klenerman
- The Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, United Kingdom
- Paul Klenerman
- 1NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
- V Aubert
- M Battegay
- E Bernasconi
- J Böni
- DL Braun
- HC Bucher
- C Burton-Jeangros
- A Calmy
- M Cavassini
- G Dollenmaier
- M Egger
- L Elzi
- J Fehr
- J Fellay
- H Furrer
- CA Fux
- M Gorgievski
- H Günthard
- D Haerry
- B Hasse
- HH Hirsch
- M Hoffmann
- I Hösli
- C Kahlert
- L Kaiser
- O Keiser
- T Klimkait
- R Kouyos
- H Kovari
- B Ledergerber
- G Martinetti
- B Martinez de Tejada
- C Marzolini
- K Metzner
- N Müller
- D Nadal
- D Nicca
- G Pantaleo
- A Rauch
- S Regenass
- C Rudin
- A Scherrer
- P Schmid
- R Speck
- M Stöckle
- P Tarr
- A Trkola
- P Vernazza
- R Weber
- S Yerly
- CV Arancibia-Cárcamo
- A Bailey
- E Barnes
- B Bird-Lieberman
- O Brain
- B Braden
- J Collier
- J East
- A Geremia
- L Howarth
- S Keshav
- P Klenerman
- S Leedham
- R Palmer
- F Powrie
- A Rodrigues
- A Simmons
- P Sullivan
- SPL Travis
- H Uhlig
- DOI
- https://doi.org/10.3389/fimmu.2018.00486
- Journal volume & issue
-
Vol. 9
Abstract
CD161 is a C-type lectin-like receptor expressed on the majority of natural killer (NK) cells; however, the significance of CD161 expression on NK cells has not been comprehensively investigated. Recently, we found that CD161 expression identifies a transcriptional and innate functional phenotype that is shared across various T cell populations. Using mass cytometry and microarray experiments, we demonstrate that this functional phenotype extends to NK cells. CD161 marks NK cells that have retained the ability to respond to innate cytokines during their differentiation, and is lost upon cytomegalovirus-induced maturation in both healthy and human immunodeficiency virus (HIV)-infected patients. These pro-inflammatory NK cells are present in the inflamed lamina propria where they are enriched for integrin CD103 expression. Thus, CD161 expression identifies NK cells that may contribute to inflammatory disease pathogenesis and correlates with an innate responsiveness to cytokines in both T and NK cells.
Keywords
- natural killer cells
- CD161
- pro-inflammatory cytokines
- cytomegalovirus
- human immunodeficiency virus
- inflammatory bowel diseases
